• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.PD-1/PD-L1 抑制剂联合胸部放疗治疗转移性肺癌患者的临床结局。
JAMA Oncol. 2018 Feb 1;4(2):253-255. doi: 10.1001/jamaoncol.2017.3808.
2
There and back again: An immunotherapy tale.往返之间：一个免疫疗法的故事。
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1771-1774. doi: 10.1016/j.jtcvs.2017.11.102. Epub 2017 Dec 23.
3
KEYNOTE-024: Unlocking a pathway to lung cancer cure?KEYNOTE-024：开启肺癌治愈之路？
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23.
4
Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.抗 PD-1 抗体在既往接受抗 PD-L1 抗体治疗的非小细胞肺癌患者中的再治疗。
Thorac Cancer. 2020 Jan;11(1):15-18. doi: 10.1111/1759-7714.13241. Epub 2019 Nov 7.
5
[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].[PD-1/PD-L1免疫检查点抑制剂在胸段癌症中的疗效及PD-L1检测]
Ann Pathol. 2017 Feb;37(1):61-78. doi: 10.1016/j.annpat.2016.12.009. Epub 2017 Feb 3.
6
Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.放疗联合抗 PD-1/PD-L1 治疗在非小细胞肺癌中的应用：迷你综述。
Clin Lung Cancer. 2018 Jan;19(1):12-16. doi: 10.1016/j.cllc.2017.06.015. Epub 2017 Jul 6.
7
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.程序性死亡-1 通路抑制剂在患有非小细胞肺癌和既往自身免疫性疾病患者中的安全性。
J Clin Oncol. 2018 Jul 1;36(19):1905-1912. doi: 10.1200/JCO.2017.77.0305. Epub 2018 May 10.
8
Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?疾病进展后再次使用PD-1/PD-L1抑制剂进行激发试验是否可行？
Immunotherapy. 2018 Apr;10(5):345-347. doi: 10.2217/imt-2017-0180.
9
Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.抗生素与中国晚期非小细胞肺癌患者抗 PD-1/PD-L1 治疗疗效减弱相关。
Lung Cancer. 2019 Apr;130:10-17. doi: 10.1016/j.lungcan.2019.01.017. Epub 2019 Jan 31.
10
Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases. 非小细胞肺癌脑转移的免疫检查点抑制剂（ICI）联合或序贯放疗。
J Cancer Res Clin Oncol. 2020 Jan;146(1):137-152. doi: 10.1007/s00432-019-03094-9. Epub 2019 Dec 7.

引用本文的文献

1
Risk factors for pneumonitis after the combination treatment of immune checkpoint inhibitors and thoracic radiotherapy.免疫检查点抑制剂与胸部放疗联合治疗后肺炎的危险因素。
BMC Pulm Med. 2025 Aug 25;25(1):404. doi: 10.1186/s12890-025-03871-y.
2
Construction of a checkpoint inhibitor-related pneumonia diagnostic model based on exhaled nitric oxide: a prospective observational study.基于呼出一氧化氮构建检查点抑制剂相关性肺炎诊断模型：一项前瞻性观察研究。
Transl Lung Cancer Res. 2025 May 30;14(5):1740-1755. doi: 10.21037/tlcr-2024-1085. Epub 2025 May 20.
3
The Treatment of Patients with Early-Stage Non-Small Cell Lung Cancer Who Are Not Candidates or Decline Surgical Resection: The Role of Radiation and Image-Guided Thermal Ablation.非小细胞肺癌早期患者不适合或拒绝手术切除的治疗：放疗和图像引导热消融的作用
J Clin Med. 2024 Dec 19;13(24):7777. doi: 10.3390/jcm13247777.
4
Role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study.基于度伐利尤单抗的免疫化疗后放疗在广泛期小细胞肺癌中的作用：一项回顾性研究。
Chin Med J (Engl). 2025 Sep 5;138(17):2130-2138. doi: 10.1097/CM9.0000000000003283. Epub 2024 Sep 23.
5
Immune checkpoint inhibitors with or without radiotherapy in metastatic non‑small cell lung cancer: A meta‑analysis and literature review.免疫检查点抑制剂联合或不联合放射治疗用于转移性非小细胞肺癌：一项荟萃分析与文献综述
Oncol Lett. 2024 Aug 9;28(4):489. doi: 10.3892/ol.2024.14622. eCollection 2024 Oct.
6
A Review of Immunotherapy in Non-Small-Cell Lung Cancer.免疫疗法在非小细胞肺癌中的研究进展
Curr Oncol. 2024 Jun 17;31(6):3495-3512. doi: 10.3390/curroncol31060258.
7
DNMT1 constrains IFNβ-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy.DNA甲基转移酶1（DNMT1）抑制IFNβ介导的抗肿瘤免疫和PD-L1表达，从而降低放疗和免疫治疗的疗效。
Oncoimmunology. 2021 Oct 21;10(1):1989790. doi: 10.1080/2162402X.2021.1989790. eCollection 2021.
8
Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.程序性细胞死亡受体 1（PD-1）抑制剂联合同期放化疗治疗复发性/转移性头颈部鳞状细胞癌患者的协同作用的初步分析。
Radiat Oncol. 2023 Jul 4;18(1):109. doi: 10.1186/s13014-023-02310-8.
9
Radiotherapy and Immunotherapy in Lung Cancer.肺癌的放射治疗与免疫治疗
Biomedicines. 2023 Jun 6;11(6):1642. doi: 10.3390/biomedicines11061642.
10
Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.放疗联合免疫检查点抑制剂治疗不可切除的局部晚期非小细胞肺癌：协同作用机制、现状、挑战和方向。
Cell Commun Signal. 2023 May 23;21(1):119. doi: 10.1186/s12964-023-01139-8.

本文引用的文献

1
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.既往放疗与帕博利珠单抗治疗非小细胞肺癌的临床活性及毒性：KEYNOTE-001 1期试验的二次分析
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.
2
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.尼伏鲁单抗单药治疗的安全性概况：晚期黑色素瘤患者的汇总分析。
J Clin Oncol. 2017 Mar;35(7):785-792. doi: 10.1200/JCO.2015.66.1389. Epub 2016 Nov 14.
3
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
4
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
5
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1（PD-1）阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
6
Immunologic correlates of the abscopal effect in a patient with melanoma.黑色素瘤患者的远隔效应的免疫相关性。
N Engl J Med. 2012 Mar 8;366(10):925-31. doi: 10.1056/NEJMoa1112824.

PD-1/PD-L1 抑制剂联合胸部放疗治疗转移性肺癌患者的临床结局。

Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.

机构信息

Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts.

Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

JAMA Oncol. 2018 Feb 1;4(2):253-255. doi: 10.1001/jamaoncol.2017.3808.

DOI:10.1001/jamaoncol.2017.3808
PMID:28973343
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5838581/
Abstract

This cohort study evaluates the clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy.

摘要

本队列研究评估了 PD-1/PD-L1 抑制剂联合胸部放疗治疗转移性肺癌患者的临床结局。